Key Takeaways & Executive Findings
- •• Moxibustion significantly reduces inflammation in acute appendicitis. • Moxibustion provides effective pain relief in acute appendicitis. • The treatment is safe and well-tolerated with no significant adverse effects. • Moxibustion can be used as an adjunctive therapy to conventional treatment.
Abstract
Objective: To evaluate the efficacy of moxibustion on acute appendicitis. Methods: A randomized controlled trial was conducted. Patients were divided into two groups: moxibustion group and control group. The moxibustion group received moxibustion treatment, while the control group received conventional treatment. Outcomes included reduction in inflammation, pain relief, and improvement in clinical symptoms. Results: The moxibustion group showed a significant reduction in inflammation and pain compared to the control group. The differences were statistically significant. Conclusion: Moxibustion is effective in reducing inflammation and pain in acute appendicitis, and can be considered as an adjunctive therapy.
1. Introduction
Acute appendicitis is a common surgical emergency characterized by inflammation of the appendix. Conventional treatment involves surgical removal of the appendix, but non-surgical approaches are being explored to reduce morbidity and healthcare costs. Moxibustion, a traditional Chinese medicine technique, has been used for various inflammatory conditions. This study aims to evaluate the efficacy of moxibustion in acute appendicitis.
The study was designed as a randomized controlled trial to compare the effects of moxibustion versus conventional treatment on inflammation and pain in patients with acute appendicitis. The results indicate that moxibustion can significantly reduce inflammation and pain, suggesting its potential as an adjunctive therapy.
Loading authentic research manuscript (Pages 1–5)...
INJ, JIY, PhI (2026). Efficacy of Moxibustion on Acute Appendicitis: A Randomized Controlled Trial. Chinese Journal of New Drugs. https://doi.org/cast_zgxyzz_1236731780393390427
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is moxibustion?
Moxibustion is a traditional Chinese medicine therapy that involves burning dried mugwort (moxa) on or near the skin to stimulate acupuncture points and promote healing.
How does moxibustion help in acute appendicitis?
Moxibustion may help reduce inflammation and pain in acute appendicitis by improving blood circulation and modulating immune responses, as shown in this study.
Is moxibustion safe for acute appendicitis?
In this study, moxibustion was safe and well-tolerated with no significant adverse effects. However, it should be used under medical supervision and not as a replacement for emergency surgery if needed.
Can moxibustion replace surgery for appendicitis?
No, moxibustion is not a replacement for surgery in cases of severe or complicated appendicitis. It may be used as an adjunctive therapy to reduce symptoms and support recovery.
What are the limitations of this study?
The study had a small sample size and was conducted at a single center. Larger multi-center trials are needed to confirm the findings.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.